​A randomized phase III study using 177Lu-PSMA-617 as a radioligand therapy in the treatment of patients with progressive, PSMA positive, metastatic castration resistant prostate cancer

​The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.

Key secondary objectives are an arm-to-arm comparison of the following:

• Radiographic progression-free survival (rPFS)
• Response Evaluation Criteria in Solid Tumors (RECIST) response
• Time to a first symptomatic skeletal event (SSE)

​Principal Investigator: Dr. Medhat Osman

This study is now closed to enrollment.

This study was funded by the Foundation through Endocyte.